What is the half-life of Ativan (lorazepam)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 26, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Half-Life of Ativan (Lorazepam)

The elimination half-life of lorazepam is approximately 12 hours in adults, with a range of 8-25 hours depending on individual patient factors. 1

Standard Adult Half-Life

  • The mean half-life of unconjugated lorazepam in human plasma is about 12 hours, as stated in the FDA drug label 1
  • Research studies consistently confirm this 12-hour half-life across multiple investigations 2, 3
  • The major metabolite, lorazepam glucuronide (which is inactive), has a slightly longer half-life of approximately 18 hours 1

Half-Life Variations by Route of Administration

  • Oral lorazepam: elimination half-life averages 12 hours (range 9.68-18.42 hours) 3, 4
  • Intravenous lorazepam: terminal half-life of 14.10 hours (±2.94 SD) 4
  • Intramuscular lorazepam: half-life of 13.6 hours, with rapid absorption reaching peak concentrations within 3 hours 5

The route of administration does not significantly alter the elimination half-life, though absorption kinetics differ 4, 5.

Pediatric Population Half-Life

  • Infants: elimination half-life is markedly prolonged at approximately 40 hours 6
  • Children: elimination half-life is approximately 10.5 hours 6

This age-dependent variation is clinically significant when converting from midazolam to lorazepam in pediatric patients, as lorazepam has a sixfold longer half-life than midazolam 7.

Special Population Considerations

Elderly Patients

  • Advancing age does not significantly affect lorazepam pharmacokinetics in most studies 1
  • However, one study showed mean total body clearance decreased by 20% in elderly subjects (60-84 years) compared to younger subjects (19-38 years) 1
  • Complete clearance time may be extended in elderly patients 6

Renal Impairment

  • The elimination half-life may be increased in patients with renal failure 6
  • Renal disease is associated with prolonged half-life and increased volume of distribution 8

Hepatic Impairment

  • Benzodiazepine clearance is reduced in patients with hepatic dysfunction 6
  • However, liver disease has minimal effect on lorazepam clearance compared to other benzodiazepines, since lorazepam undergoes direct glucuronidation rather than oxidative metabolism 8

Clinical Implications

  • Steady-state blood levels occur within 2-3 days of multiple dosing and are directly proportional to the daily dose 2
  • The active drug and glucuronide conjugate are completely eliminated from the blood within 1 week following the last dose 2
  • For procedural sedation, patients require monitoring for up to 2 hours post-administration of IV lorazepam 9
  • When weaning from continuous IV benzodiazepines, the required time is proportional to the duration of treatment, and lorazepam's longer half-life must be factored into clinical decision-making 7, 6

References

Research

Clinical pharmacokinetics of lorazepam: a review.

The Journal of clinical psychiatry, 1978

Research

Clinical pharmacokinetics of lorazepam. II. Intramuscular injection.

Clinical pharmacology and therapeutics, 1977

Guideline

Lorazepam Clearance and Metabolism

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Clinical pharmacokinetics of oxazepam and lorazepam.

Clinical pharmacokinetics, 1981

Guideline

Duration of Action of IV Lorazepam

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.